Scarica l'app Stockscreener
644.61
0.16%
1.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IDXX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$643.59
Aprire:
$642.39
Volume 24 ore:
562.43K
Relative Volume:
1.00
Capitalizzazione di mercato:
$51.47B
Reddito:
$4.30B
Utile/perdita netta:
$1.06B
Rapporto P/E:
49.30
EPS:
13.076
Flusso di cassa netto:
$1.04B
1 W Prestazione:
-3.86%
1M Prestazione:
-8.80%
6M Prestazione:
+3.27%
1 anno Prestazione:
+39.96%
Intervallo 1D:
$639.02
$650.38
Intervallo di 1 settimana:
$622.37
$658.75
Portata 52W:
$356.14
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Nome
Idexx Laboratories Inc
Settore
Industria
Telefono
(207) 556-0300
Indirizzo
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
644.61 | 51.39B | 4.30B | 1.06B | 1.04B | 13.08 |
|
TMO
Thermo Fisher Scientific Inc
|
542.83 | 203.77B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
216.61 | 152.51B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
A
Agilent Technologies Inc
|
129.58 | 36.75B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
187.49 | 30.69B | 15.90B | 1.28B | 2.21B | 7.2842 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-31 | Aggiornamento | Stifel | Hold → Buy |
| 2025-10-01 | Iniziato | UBS | Neutral |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-01 | Iniziato | Jefferies | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | BTIG Research | Buy |
| 2024-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-12-04 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2023-08-02 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | Downgrade | Stifel | Buy → Hold |
| 2022-07-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-07-12 | Iniziato | Piper Sandler | Overweight |
| 2022-05-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-08 | Iniziato | Atlantic Equities | Overweight |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-17 | Iniziato | Barclays | Overweight |
| 2019-09-09 | Iniziato | Goldman | Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Buy |
| 2018-11-02 | Reiterato | BofA/Merrill | Buy |
| 2018-05-07 | Reiterato | Stifel | Buy |
| 2018-01-16 | Iniziato | Piper Jaffray | Overweight |
| 2017-08-23 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | Aggiornamento | CL King | Neutral → Buy |
| 2017-02-03 | Downgrade | Feltl & Co. | Hold → Sell |
| 2016-09-29 | Ripresa | BofA/Merrill | Neutral |
| 2016-08-16 | Reiterato | Stifel | Buy |
| 2016-08-03 | Aggiornamento | Northcoast | Sell → Neutral |
| 2016-07-20 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-19 | Reiterato | Canaccord Genuity | Buy |
| 2016-04-01 | Iniziato | CL King | Neutral |
| 2016-03-21 | Reiterato | Stifel | Buy |
| 2016-02-04 | Iniziato | Credit Suisse | Outperform |
| 2015-10-29 | Reiterato | Stifel | Buy |
| 2015-08-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | Reiterato | Stifel | Buy |
| 2015-07-23 | Reiterato | Canaccord Genuity | Buy |
Mostra tutto
Idexx Laboratories Inc Borsa (IDXX) Ultime notizie
IDEXX Laboratories, Inc. (IDXX): A Bull Case Theory - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Qiagen (QGEN) and InnovAge Holding (INNV) - The Globe and Mail
Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating - marketscreener.com
4 Analysts Have This To Say About IDEXX Laboratories - Benzinga
IDEXX Laboratories (IDXX) Positioned to Benefit from Growing Aging Pet Market - Finviz
Fidelity Growth Strategies Fund Avoids IDEXX Laboratories (IDXX) Due to Questionable Growth Durability - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Idexx Laboratories (IDXX) and West Pharmaceutical Services (WST) - The Globe and Mail
Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850 - marketscreener.com
Idexx Laboratories executive vice president sells $4.6 million in stock - MSN
IDEXX: A Great Business Trapped By A Demanding Valuation (NASDAQ:IDXX) - Seeking Alpha
Hantz Financial Services Inc. Decreases Stake in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Alta Capital Management LLC Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX - MarketBeat
Rep. April McClain Delaney Sells Off Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX) and Lonza Group (OtherLZAGY) - The Globe and Mail
A Quick Look at Today's Ratings for IDEXX Laboratories Inc(IDXX.US), With a Forecast Between $730 to $805 - 富途牛牛
IDEXX Laboratories Analysts Cut Their Forecasts Following Q4 Results - Benzinga
Roku To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830 - marketscreener.com
UBS Adjusts IDEXX Laboratories PT to $730 From $750 - marketscreener.com
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2025 earnings call transcript - MSN
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2025 Earnings Call Transcript - Insider Monkey
BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830 - marketscreener.com
Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700 - marketscreener.com
IDEXX Laboratories, Inc. $IDXX Shares Sold by Villere ST Denis J & Co. LLC - MarketBeat
Thrivent Financial for Lutherans Has $38.68 Million Stake in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories: Can This Quiet Diagnostics Powerhouse Still Surprise Wall Street? - AD HOC NEWS
BTIG Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating, Cuts Target Price to $800 - 富途牛牛
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: A 14.25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Idexx Laboratories (IDXX) Margin Strength Reinforces Bullish Narrative Despite Premium P/E - Sahm
Earnings call transcript: IDEXX Labs Q4 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: IDEXX Labs Q4 2025 misses EPS, stock dips - Investing.com Canada
IDEXX Laboratories (NASDAQ:IDXX) Trading Down 6.9%Should You Sell? - MarketBeat
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
IDEXX Laboratories Inc (IDXX) Q4 2025 Earnings Call Highlights: - GuruFocus
IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise - The Globe and Mail
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - 富途牛牛
Why Is IDEXX Labs Stock Falling Today? - Benzinga
IDEXX Laboratories Q4 Earnings Call Highlights - MarketBeat
IDEXX Laboratories (IDXX) Reports Strong Q4 2025 Performance - GuruFocus
RSI Alert: Idexx Laboratories (IDXX) Now Oversold - Nasdaq
IDEXX Laboratories Reports 14% Q4 Revenue Growth Driven by Premium Instrument Placements - Market Business Insights
IDEXX falls 4% following in-line 2026 guidance - Seeking Alpha
IDEXX beats the Street on Q4 results, issues initial 2026 guidance - Mainebiz
AI for investors - MLQ.ai
IDEXX Laboratories (NASDAQ:IDXX) Updates FY 2026 Earnings Guidance - MarketBeat
Earnings Summary: IDEXX Laboratories Q4 - Benzinga
IDEXX forecasts 2026 revenue, profit above estimates on strong demand for pet diagnostics - marketscreener.com
Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
IDEXX Laboratories (IDXX) Q4 FY25 sales rise in double digits - AlphaStreet
IDEXX Laboratories (NASDAQ:IDXX) Announces Quarterly Earnings Results - MarketBeat
IDEXX LABORATORIES INC (NASDAQ:IDXX) Reports Strong Q4 2025 Earnings Beat, Issues Cautious 2026 Outlook - Chartmill
Idexx Laboratories Inc Azioni (IDXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
3.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):